

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor

•

Gerard M. HOUSEY

Serial No.

Unassigned

Filing Date

Unassigned

For:

o massigned

INHIBITORS AND ACTIVATORS

METHOD FOR SCREENING FOR PROTEIN

Examiner

•

Unassigned

Art Unit

:

Unassigned

Assistant Commissioner for Patents Washington D.C. 20231

PRELIMINARY AMENDMENT

Sir:

Prior to examination, please amend the above application for patent as follows.

Please cancel claims 1-30, and add the following claims:

31. A pharmaceutical composition for treating a disease or other condition for which therapeutic treatment could be beneficial, which comprises a therapeutically effective amount of an inhibitor or activator of a protein which was characterized as an inhibitor or activator of the protein at least in part through a process comprising the steps of:

(a) selecting a substance, which had not been previously administered as a treatment for the disease or other condition;

0 pholude

1.05 Gran Gran Gran G. 10.00

12.25

Page 1 of 3

Mondade

- (b) providing a test cell in which the protein is present at a higher level relative to a control cell which produces the protein at a lower level or essentially does not produce the protein, and wherein production of the protein in the test cell evokes a responsive change in a phenotypic characteristic, other than the level of the protein in the cell, per se, which is comparatively greater than in the control cell;
- (c) treating the test cell containing the protein with the substance; and
- (d) examining the treated test cell to determine whether it exhibits a change in the phenotypic characteristic in response to the substance.
- 32. A substance which is an inhibitor or activator of a protein, the protein being functionally related to a disease or other condition for which therapeutic treatment could be beneficial, which was characterized as an inhibitor or activator of the protein at least in part through a process comprising the steps of:
 - (a) selecting a substance which had not been previously administered for treatment of the disease or other condition;
 - (b) providing a test cell in which the protein is present at a higher level relative to a control cell which produces the protein at a lower level or essentially does not produce the protein, and wherein production of the protein in the test cell evokes a responsive change in a phenotypic characteristic, other than the level of the protein in the cell, per se, which is comparatively greater than in the control cell;
 - (c) treating the test cell containing the protein with the substance; and